| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6340475 | DEPOMED INC | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6635280 | DEPOMED INC | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US5972389 | DEPOMED INC | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
Sep, 2016
(7 years ago) | |
| US6488962 | DEPOMED INC | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(3 years ago) | |
Proquin Xr is owned by Depomed Inc.
Proquin Xr contains Ciprofloxacin Hydrochloride.
Proquin Xr has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Proquin Xr are:
- US6340475
- US6635280
- US5972389
- US6488962
Proquin Xr was authorised for market use on 19 May, 2005.
Proquin Xr is available in tablet, extended release;oral dosage forms.
Proquin Xr can be used as the treatment of uncomplicated urinary tract infections.
The generics of Proquin Xr are possible to be released after 20 June, 2020.
Drugs and Companies using CIPROFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 19 May, 2005
Treatment: The treatment of uncomplicated urinary tract infections
Dosage: TABLET, EXTENDED RELEASE;ORAL
PROQUIN XR family patents
